Activity of compound 506U78 in patients with refractory T-cell malignancies: A POG/CCG intergroup phase 2 study.

被引:0
|
作者
Berg, SL
Blaney, SM
Bernstein, M
Kurtzberg, J
Devidas, M
Lampkin, T
Murgo, AJ
Harris, MB
机构
[1] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA
[2] Hop St Justine, Montreal, PQ H3T 1C5, Canada
[3] Duke Univ, Med Ctr, Durham, NC 27706 USA
[4] Childrens Oncol Grp, Gainesville, FL USA
[5] GlaxoSmithKline, Collegeville, PA USA
[6] NCI, Invest Drug Branch, Canc Therapy Evaluat Program, Rockville, MD USA
[7] Hackensack Univ, Tomorrow Childrens Inst, Med Ctr, Hackensack, NJ USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
792
引用
收藏
页码:226A / 226A
页数:1
相关论文
共 50 条
  • [31] Phase I/II study of oral fodosine™, a PNP inhibitor in refractory cutaneous T-cell lymphoma patients
    Duvic, M
    Breneman, D
    Cooper, M
    Fonseca, G
    Bennett, JC
    Kilpatrick, JM
    Bantia, S
    BLOOD, 2005, 106 (11) : 753A - 753A
  • [32] Forodesine (Fodosine™), a PNP inhibitor active in relapsed or refractory T-cell leukemia patients -: (Phase II study).
    Furman, RR
    Iosava, G
    Isola, L
    Ravandi, F
    Zodelava, M
    Bennett, JC
    Kilpatrick, JM
    Bantia, S
    BLOOD, 2005, 106 (11) : 259A - 259A
  • [33] Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"
    Tournilhac, Olivier
    Hacini, Maya
    Bouabdallah, Kamal
    Laribi, Kamel
    Maerevoet, Marie
    Ysebaert, Loic
    Guidez, Stephanie
    Le Gouill, Steven
    Andre, Marc
    Dupuis, Jehan
    Thieblemont, Catherine
    Bachy, Emmanuel
    Daguindau, Nicolas
    Morschhauser, Franck
    Tricot, Sabine
    Feugier, Pierre
    Banos, Anne
    De la Chapelle, Thierry Lamy
    Chauchet, Adrien
    Gyan, Emmanuel
    Cartron, Guillaume
    Farhat, Hassan
    Camus, Vincent
    Drenou, Bernard
    Zerazhi, Hacene
    Sibon, David
    Nicolas-Virelizier, Emmanuelle
    Delette, Caroline
    Snauwaert, Sylvia
    Straetmans, Nicole
    Delarue, Richard
    Parrens, Marie
    Bossard, Celine
    De Leval, Laurence
    Gaulard, Philippe
    Damaj, Gandhi Laurent
    BLOOD, 2020, 136
  • [34] Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study
    Maruyama, Dai
    Tobinai, Kensei
    Ogura, Michinori
    Uchida, Toshiki
    Hatake, Kiyohiko
    Taniwaki, Masafumi
    Ando, Kiyoshi
    Tsukasaki, Kunihiro
    Ishida, Takashi
    Kobayashi, Naoki
    Ishizawa, Kenichi
    Tatsumi, Yoichi
    Kato, Koji
    Kiguchi, Toru
    Ikezoe, Takayuki
    Laille, Eric
    Ro, Tokihiro
    Tamakoshi, Hiromi
    Sakurai, Sanae
    Ohtsu, Tomoko
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (05) : 655 - 665
  • [35] Phase I/II Multicenter Study of Romidepsin in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Ogura, Michinori
    Maruyama, Dai
    Tobinai, Kensei
    Uchida, Toshiki
    Hatake, Kiyohiko
    Taniwaki, Masafumi
    Ando, Kiyoshi
    Tsukasaki, Kunihiro
    Ishida, Takashi
    Kobayashi, Naoki
    Ishizawa, Kenichi
    Tatsumi, Yoichi
    Kato, Koji
    Kiguchi, Toru
    Ikezoe, Takayuki
    Laille, Eric
    Ro, Tokihiro
    Tamakoshi, Hiromi
    Sakurai, Sanae
    Ohtsu, Tomoko
    BLOOD, 2016, 128 (22)
  • [36] Oral forodesine (Bcx-1777) is clinically active in refractory cutaneous T-cell lymphoma: Results of a phase I/II study.
    Duvic, Madeleine
    Forero-Torres, Andres
    Foss, Francine
    Olsen, Elsie A.
    Kim, Youn
    BLOOD, 2006, 108 (11) : 698A - 698A
  • [37] A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL)
    Falchi, Lorenzo
    Lue, Jennifer Kimberly
    Amengual, Jennifer E.
    Sawas, Ahmed
    Deng, Changchun
    Marchi, Enrica
    Lichtenstein, Emily
    Khan, Karen
    Kim, Hyea
    Atkins, Laine E.
    Rada, Aishling M.
    Rojas, Celeste
    Serge, Cremers
    O'Connor, Owen A.
    BLOOD, 2017, 130
  • [38] A Phase '2-1-2' study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier (RFC-1), in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies
    O'Connor, Owen A.
    Hamlin, Paul
    Portlock, Carol
    Moskowitz, Craig
    Noy, Ariela
    Straus, David
    Dumetrescu, Otila
    Sarasohn, Debra
    Neylon, Ellen
    Hamelers, Rachel
    MacGregor-Cortelli, Barbara
    Pappanicolu, Jennifer
    Zelentz, Andrew
    Sirotnak, Frank
    Fleischer, Martin
    Mould, Diane
    Saunders, Michael
    Horwitz, Steven
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3554S - 3554S
  • [39] Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Witzig, Thomas E.
    Sokol, Lubomir
    Kim, Won Seog
    de la Cruz Vicente, Fatima
    Caballero, Dolores
    Advani, Ranjana
    de Ona, Raquel
    Marin Niebla, Ana
    Jose Terol, Maria
    Domenech Eva, Domingo
    Bendris, Nawal
    Mackey Ahsan, Julie
    Leoni, Mollie
    Foss, Francine M.
    BLOOD, 2021, 138
  • [40] Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"
    Tournilhac, Olivier
    Lecolant, Solene
    Hacini, Maya
    Bouabdallah, Krimo
    Bailly, Sebastien
    Laribi, Kamel
    Belmondo, Thibaut
    Maerevoet, Marie
    Ysebaert, Loic
    Guidez, Stephanie
    Le Gouill, Steven
    Bonnet, Christophe
    Andre, Marc
    Dupuis, Jehan
    Thieblemont, Catherine
    Bachy, Emmanuel
    Daguindau, Nicolas
    Morschhauser, Franck
    Tricot, Sabine
    Feugier, Pierre
    Banos, Anne
    Lamy, Thierry
    Chauchet, Adrien
    Gyan, Emmanuel
    Cartron, Guillaume
    Farhat, Hassan
    Camus, Vincent
    Drenou, Bernard
    Zerazhi, Hacene
    Sibon, David
    Nicolas-Virelizier, Emmanuelle
    Delette, Caroline
    Snauwaert, Sylvia
    Straetmans, Nicole
    Delarue, Richard
    Parrens, Marie
    Griolet, Samuel
    Gaulard, Philippe
    Delfau-Larue, Marie-Helene
    De Leval, Laurence
    Damaj, Gandhi Laurent
    BLOOD, 2022, 140 : 2302 - 2305